Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04866641Phase 1Recruiting

Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors

Role: lead

NCT04685473Phase 1Active Not Recruiting

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors

Role: lead

NCT05156203Phase 1Recruiting

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

Role: lead

NCT03195764Phase 1Terminated

Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Role: lead

NCT03349073Phase 1Completed

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Role: lead

All 5 trials loaded